Welcome to the 3rd annual conference dedicated to soft mist inhalers (SMI). Learn to make, develop, use, file, launch SMIs, and their place in an inhaled therapy portfolio.
SMIs are capturing 50% of the portable inhaler market. They are THE inhaler device choice for low carbon footprint and for deep lung deposition for local and systemic action. SMIs are versatile, user-friendly, easy to formulate and easily implemented in an inhaler portfolio. SMIs love biologics therapies.
SMI.London 2025 will carry on the conversation on soft mist inhalers started in 2023.
The conference will illustrate how SMIs are taking their place alongside other inhalers and what benefits their bring. The day will explore the regulatory and scientific context in which SMIs are developed. It will chart the path from molecules to finished dosage forms. The event will include talks by key opinion leaders with extensive experience in the field of Inhaled Drug Delivery.
SMI.London will be take place on Wednesday 25 June 2025 at the Pullman London St Pancras.
Exhibition opportunities are available for product and service providers.
Inhalation Drug Delivery: Make It Better
Seeing Through The Mist: SMI Spray Characterization
Importance of automated actuation for testing for SMI devices
Considerations for Spray Characterizations testing of SMI products
Additional learnings from the use of “Playback” tools
Plume Front Velocity and Spray Duration measurements for novel drugs and generics Deposition tools for SMI
Aerosolization Of Wegovy With MRX004 (SMI)
Wegovy® commercial injection formulations were successfully aerosolised with MRX004
The integrity of Semaglutide was preserved on aerosolisation
The FPF of Wegovy® 0.25mg/05ml in MRX004 was 53% with a FPD 3 μg
The FPF of Semaglutide 10 mg/ml in MRX004 was 52% with a FPD of 55 μg
Inhaled drug delivery of GLP-1 analogues is a viable alternative to injections
Aseptic Filling Machine: Development Step To Commercial Production
Enhancing drug safety with AFM through closed-system sterile filling
Exploring therapeutic applications made possible by AFM technology
Driving formulation and testing
Scaling up from formulation to industrial production
Sterility or low bioburden as CQA for the finished product
Expanding The SMI World: Options & Applications
Principles of Pre-Filled Syringe Soft Mist Inhaler, advantages of an integrated primary package
SMIs as an option for the delivery of delicate biologics
Re-purposing existing drugs for improved delivery and patient comfort
Extending soft mist principles to nasal delivery, enabling effective CNS therapies
Links Between Solution Properties, Spray And Lung Deposition In Soft Mist Inhalers.
The goal of this study was to understand design space and understand lung deposition of these tricker systems
As we move towards formulating more complex molecules into SMIs (think larger biological molecules, polymeric excipients, higher concentrations etc.) we are going to end up with wider ranges in formulation physical properties such as viscosity and surface tension
Solutions with a range of non-Newtonian rheology and different surface tensions were prepared to see which ones we could spray out of a Respimat SMI
We measured the spray properties (droplet size, velocity, spray pattern) of this that aerosolised
These data were then input into our deposition models to understand how this all links to lung deposition
PULLMAN LONDON ST PANCRAS
100-110 EUSTON ROAD
London
NW1 2AJ
UK
25 June 2025
Located in King’s Cross, the contemporary stylish and cosmopolitan Pullman London St Pancras is the venue of choice for SMI.London 2025.
Registration, refreshments & networking
Chair of session 1: Mr. Chris Vernall, Director, CV Respiratory
Introducing SMI.London 2025
Dr. Philippe Rogueda, Chief Business Officer, Merxin Ltd
Speed Networking
Talk to your neighbours. Greet people you have never met before.
Exploring Nasal siRNA-LNP SMI Therapies
Professor Daniela Traini, Professor of Respiratory Science, Woolcock Institute of Medical Research, Macquarie University and Ab Initio Pharma
Role of siRNA in treating respiratory diseases
Limitations of current delivery methods
Rationale for using lipid nanoparticles (LNPs) and SMI nasal delivery
In Vitro Assessment of Aerosol Performance
In Vivo Evaluation in an infected animal model
LNPs & SMIs: Extending Formulation & Treatment Options
Dr. Rémi Rosière, Chief Scientific Officer, Co-founder, InhaTarget Therapeutics
Combination of LNP and SMI as a promising pulmonary drug delivery platform
Potential drug cargo for inhalation and new indications
LNP formulation options for multiple drug cargo
Focus on inhaled immunotherapy for lung cancers
Coffee break & networking
Chair of session 2: Dr. Peter Hirst, Consultant, Peter Hirst Consulting Ltd
Seeing Through The Mist: SMI Spray Characterization
Dr. Deborah Jones, Director of Sales, EMEIA, Proveris Laboratories
Importance of automated actuation for testing for SMI devices
Considerations for Spray Characterizations testing of SMI products
Additional learnings from the use of “Playback” tools
Plume Front Velocity and Spray Duration measurements for novel drugs and generics
Deposition tools for SMI
Aseptic Filling Machine: Development Step To Commercial Production
Mrs. Laury Livemont, Industrial Development Manager, Unither Pharmaceuticals
Enhancing drug safety with AFM through closed-system sterile filling
Exploring therapeutic applications made possible by AFM technology
Driving formulation and testing
Scaling up from formulation to industrial production
Sterility or low bioburden as CQA for the finished product
Innovating Spray Nozzle Technology: How Microfluidic Manufacturing Drives Precision
Dr.-Ing. Christian Walk (Business Development Manager) and Dr. Marko Blom (Chief Technology Officer), Micronit B.V.
Soft Mist Spray nozzles
Colliding Jet
Rayleigh Jet
Nozzle Manufacturing
Silicon and Glas
Lunch, Exhibition & networking
Chair of session 3: Dr. Jenny Lam, Associate Professor of Pharmaceutics, UCL School of Pharmacy
Aerosolization Of Wegovy® With MRX004 (SMI)
Dr. Philippe Rogueda, Chief Business Officer, Merxin Ltd
Wegovy® commercial injection formulations were successfully aerosolised with MRX004
The integrity of Semaglutide was preserved on aerosolisation
The FPF of Wegovy® 0.25mg/05ml in MRX004 was 53% with a FPD 3 μg
The FPF of Semaglutide 10 mg/ml in MRX004 was 52% with a FPD of 55 μg
Inhaled drug delivery of GLP-1 analogues is a viable alternative to injections
Expanding The SMI World: Options & Applications
Dr. Nicolas Buchmann, Chief Technology Officer, Resyca B.V.
Principles of Pre-Filled Syringe Soft Mist Inhaler, advantages of an integrated primary package
SMIs as an option for the delivery of delicate biologics
Re-purposing existing drugs for improved delivery and patient comfort
Extending soft mist principles to nasal delivery, enabling effective CNS therapies
Links Between Solution Properties, Spray and Lung Deposition In Soft Mist Inhalers
Dr. Khaled Alzahabi, Nasal and Pulmonary Drug Delivery Formulation Specialist, Nanopharm, an Aptar Pharma Company
The goal of this study was to understand design space and understand lung deposition of these tricker systems
As we move towards formulating more complex molecules into SMIs (think larger biological molecules, polymeric excipients, higher concentrations etc.) we are going to end up with wider ranges in formulation physical properties such as viscosity and surface tension
Solutions with a range of non-Newtonian rheology and different surface tensions were prepared to see which ones we could spray out of a Respimat SMI
We measured the spray properties (droplet size, velocity, spray pattern) of this that aerosolised
These data were then input into our deposition models to understand how this all links to lung deposition
Coffee break & networking
Chair of session 4: Mr. Chris Hall, Chairman, Merxin Ltd
Panel discussion & final remarks
Close of the day
Register for SMI.London 2025 here
£695 +VAT
Would you like to be part of the SMI.London 2025 exhibition?
A limited number of table-top exhibition options are available. Exhibition benefits include:
Physical presence at the event
Table-top or space for exhibiting your services and products
2 free registrations for your staff
Full participants’ list post event
Full listing on the conference website
Acknowledgement on social media and SMI.London 2025 communications
The exhibition fee: £3,250 (excl UK VAT). Please email info@smi.london to book your space.
Please visit our previous year's here: